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TO THE EDITOR
We appreciate the interest in our recent article [1] on biomarkers in Ebola virus disease 
(EVD) and the editorial comments provided by Fedson. In his editorial, Fedson points out 
that the evidence of endothelial dysfunction that we reported in patients affected by EVD is 
also commonly observed in other forms of sepsis. He brings attention to a mouse study that 
indicated that selective inhibition of nuclear factor κB signaling in endothelial cells in the 
context of bacterial sepsis provided protection from disease [2], suggesting that 
downregulation of the local inflammatory response at the endothelial cell level could be 
protective to patients. Additionally, he comments on a small clinical trial of statins in 
patients with sepsis; this study showed decreased progression to severe sepsis in statin-
treated patients [3]. This result is attributed to the role of statins in stabilizing the 
endothelium and in its local antiinflammatory effects on endothelial cells. Finally, Fedson 
suggests the use of statins as adjunctive therapy in managing patients who have EVD.
We agree that statins should be considered as adjunctive therapy for EVD. In fact, we 
suggested the use of statins in patients with EVD in a subsequent study, in which we 
examined the differences in biomarkers and clinical outcomes between adult and pediatric 
patients with EVD [4]. In that study, we observed direct evidence of endothelial 
dysfunction, demonstrated by elevated levels of soluble intercellular adhesion molecule and 
soluble vascular cell adhesion molecule in pediatric patients who had fatal outcomes, and 
normal levels of these factors in pediatric patients who survived infection.
No treatment is without risk, however, and the benefits and risks of a given intervention or 
medication must always be considered. The risks of using statins include rhabdomyolysis, 
leading to acute renal failure, and many potential drug interactions, since statins are 
metabolized by the cytochrome P450 system. Also, patients with known elevation of hepatic 
transaminase levels are at increased risk of side effects. Since Ebola virus is known to be 
hepatotrophic and severe disease is associated with elevated hepatic transaminase levels, 
patients would need to be carefully monitored if statins were initiated. This type of intensive 
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monitoring could be very difficult to achieve in the areas of the world affected by EVD. On 
the other hand, use of statins in patients with EVD could stabilize the endothelium by 
decreasing local inflammation and, thus, lessen the risk of the patient developing shock. 
Additionally, although only 30%–40% of patients develop hemorrhagic manifestations of 
EVD and because the presence of hemorrhage does not correlate with death, statin use might 
also decrease the incidence of hemorrhage by affecting components of the coagulation 
pathway.
Unanswered questions include the dose, frequency, duration, and choice of statin to use in 
patients with EVD. Presumably, initiating statin treatment within 24 hours of the onset of 
symptoms would be best, although given the severity of untreated EVD, initiation of 
treatment at any point in the disease course would be reasonable. In the ASEPSIS trial, 40 
mg of atorvastatin was administered daily for the duration of hospitalization, up to 28 days. 
Patients who survive EVD tend to show recovery within 2 weeks of symptom onset, so this 
duration of therapy would theoretically be sufficient. Typically, a potentially useful drug 
would be evaluated in several animal models of disease long before its use in humans is 
even considered. Then, a rigorous, double-blinded, placebo-controlled trial would be 
conducted to evaluate that drug in humans. However, we are in the midst of the largest EVD 
outbreak ever recorded, and it shows no signs of abating. Therefore, the individual clinician 
is left with the decision to use a drug off-label that might be beneficial, while weighing the 
possible side effects of that drug. These decisions should be made very carefully, in 
consultation with the patient, and with full disclosure of the possible risks and benefits.
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